Clinical investigator Kevin R. Bender failed to secure a controlled investigational drug, and 110 kits were stolen.
What happened
FDA inspected Dr. Bender’s clinical site on December 5–16, 2022, as part of its Bioresearch Monitoring Program and reviewed conduct of three clinical investigations. FDA found that an investigational drug classified as a DEA Schedule III controlled substance was stored outside the designated locked cabinet in a locked room accessible to people other than designated study staff, contrary to 21 CFR 312.69 and the protocol. The letter states that 110 kits received on December 2, 2021, were missing due to customer/nonemployee theft, reported to the study monitor on March 10, 2022, and to DEA on April 1, 2022.
What FDA found
The site did not store a Schedule III investigational drug in a securely locked, limited-access cabinet, and 110 kits were reported missing due to theft.
21 CFR 312.69The investigator did not follow the protocol’s requirements for secured, monitored, limited-access storage and restricted access to study drug.
21 CFR 312.60
What FDA wants
Within 15 business days of receipt, notify FDA in writing of actions taken to prevent similar violations and include sufficient detail on access limits and training; failure may lead to regulatory action.
Who should pay attention
- clinical trial sites handling controlled substances
- sponsors and monitors of investigational drug studies
- contract research organizations overseeing site compliance
This is a summary. Read the original letter on fda.gov.